CRTHF (CARsgen Therapeutics Holdings) Beneish M-Score: -0.41 (As of Jul. 08, 2026)


CRTHF CARsgen Therapeutics Holdings Ltd CRTHF
24 GF Score
Price $2.08
! 3 Warning Signs
View Full Analysis

What is CARsgen Therapeutics Holdings Beneish M-Score?

CARsgen Therapeutics Holdings CRTHF 24 Beneish M-Score is -0.41 as of Jul. 08, 2026. GuruFocus rates CRTHF with a GF Score™ of 24/100. The stock has 3 warning signs investors should review. Among 822 Biotechnology companies, CARsgen Therapeutics Holdings ranks worse than 82.36% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score -0.41 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for CARsgen Therapeutics Holdings's Beneish M-Score or its related term are showing as below:

CRTHF' s Beneish M-Score Range Over the Past 10 Years
Min: -0.41   Med: -0.41   Max: -0.41
Current: -0.41

During the past 7 years, the highest Beneish M-Score of CARsgen Therapeutics Holdings was -0.41. The lowest was -0.41. And the median was -0.41.


CARsgen Therapeutics Holdings Beneish M-Score Historical Data

* Premium members only.

The historical data trend for CARsgen Therapeutics Holdings's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CARsgen Therapeutics Holdings Beneish M-Score Chart

CARsgen Therapeutics Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 -0.41

CARsgen Therapeutics Holdings Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -0.41

CRTHF vs VRTX, REGN, ALNY: Beneish M-Score Comparison

For the Biotechnology subindustry, CARsgen Therapeutics Holdings's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CARsgen Therapeutics Holdings Beneish M-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CARsgen Therapeutics Holdings's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where CARsgen Therapeutics Holdings's Beneish M-Score falls into.


CRTHF
24GF Score
CARsgen Therapeutics Holdings Ltd CRTHF
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CARsgen Therapeutics Holdings Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of CARsgen Therapeutics Holdings for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.3533+0.528 * 0.5878+0.404 * 1.1571+0.892 * 3.2949+0.115 * 1.6591
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.1572+4.679 * 0.107604-0.327 * 0.8498
=-0.41

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Total Receivables was $4.36 Mil.
Revenue was $17.84 Mil.
Gross Profit was $11.35 Mil.
Total Current Assets was $167.27 Mil.
Total Assets was $183.46 Mil.
Property, Plant and Equipment(Net PPE) was $13.10 Mil.
Depreciation, Depletion and Amortization(DDA) was $4.19 Mil.
Selling, General, & Admin. Expense(SGA) was $3.70 Mil.
Total Current Liabilities was $29.17 Mil.
Long-Term Debt & Capital Lease Obligation was $6.86 Mil.
Net Income was $-13.89 Mil.
Gross Profit was $0.00 Mil.
Cash Flow from Operations was $-33.64 Mil.
Total Receivables was $3.75 Mil.
Revenue was $5.42 Mil.
Gross Profit was $2.03 Mil.
Total Current Assets was $210.18 Mil.
Total Assets was $229.79 Mil.
Property, Plant and Equipment(Net PPE) was $16.26 Mil.
Depreciation, Depletion and Amortization(DDA) was $10.93 Mil.
Selling, General, & Admin. Expense(SGA) was $7.15 Mil.
Total Current Liabilities was $34.89 Mil.
Long-Term Debt & Capital Lease Obligation was $18.23 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(4.361 / 17.842) / (3.746 / 5.415)
=0.244423 / 0.691782
=0.3533

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(2.025 / 5.415) / (11.351 / 17.842)
=0.373961 / 0.636195
=0.5878

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (167.266 + 13.1) / 183.459) / (1 - (210.182 + 16.26) / 229.79)
=0.016859 / 0.01457
=1.1571

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=17.842 / 5.415
=3.2949

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(10.927 / (10.927 + 16.26)) / (4.188 / (4.188 + 13.1))
=0.40192 / 0.242249
=1.6591

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(3.702 / 17.842) / (7.145 / 5.415)
=0.207488 / 1.319483
=0.1572

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((6.863 + 29.171) / 183.459) / ((18.225 + 34.888) / 229.79)
=0.196414 / 0.231137
=0.8498

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-13.894 - 0 - -33.635) / 183.459
=0.107604

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

CARsgen Therapeutics Holdings has a M-score of -0.41 signals that the company is likely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -0.41 mean?
CARsgen Therapeutics Holdings (CRTHF) has a Beneish M-Score of -0.41 as of Jul. 08, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on CARsgen Therapeutics Holdings and its competitors. According to the industry distribution chart, CARsgen Therapeutics Holdings ranks #677 out of 822 companies in the Biotechnology industry, placing it in the top 82.4%.
Is CARsgen Therapeutics Holdings' Beneish M-Score too high?
CARsgen Therapeutics Holdings' current Beneish M-Score is -0.41. Based on the distribution chart, CARsgen Therapeutics Holdings ranks #677 out of 822 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, CARsgen Therapeutics Holdings has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does CARsgen Therapeutics Holdings' Beneish M-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CARsgen Therapeutics Holdings ranks #677 out of 822 companies for Beneish M-Score. This places CARsgen Therapeutics Holdings in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Biotechnology company?
A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on CARsgen Therapeutics Holdings and its competitors. CARsgen Therapeutics Holdings's current Beneish M-Score is -0.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CARsgen Therapeutics Holdings stock overvalued right now?
CARsgen Therapeutics Holdings (CRTHF) has a current Beneish M-Score of -0.41. The current Beneish M-Score is -0.41. CARsgen Therapeutics Holdings' overall GF Score™ is 24/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For CARsgen Therapeutics Holdings (CRTHF), the current Beneish M-Score is -0.41 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CARsgen Therapeutics Holdings Business Description

Other Exchanges 02171:Hong Kong
Address No. 466 Yindu Road, Building 2, 1st Floor, Xuhui District, Shanghai, CHN
CARsgen Therapeutics Holdings Ltd is a clinical-stage biopharmaceutical company discovering, researching, and developing cell therapies in the People's Republic of China and the United States of America. During the year, a majority of the Group's revenue was derived from one customer located in the Chinese mainland.
24GF Score

Get the complete analysis for CRTHF

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.08
Price